US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ashland

50.48

+0.93001.88%

Post-market: 50.480.00000.00%16:07 EDT

Volume:404.29K

Turnover:20.42M

Market Cap:2.38B

PE:-110.09

High:50.98

Open:49.91

Low:49.73

Close:49.55

Loading ...

Overview Company News Filings

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

BLRX: Ayrmid Assumes Commercialization Efforts

Zacks Small Cap Research

INEOS Enterprises to sell composites business for about $1.79 bln

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Adaptive Biotechnologies announces 65 abstracts to be presented at ASH meeting

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Innate Pharma SA’s Innovations Spotlighted at ASH 2024

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers at ESMO Asia, SABCS and ASH

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ASH/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASH\",,,,,undefined,":{"symbol":"ASH","market":"US","secType":"STK","nameCN":"Ashland","latestPrice":50.48,"timestamp":1744920000000,"preClose":49.55,"halted":0,"volume":404291,"hourTrading":{"tag":"盘后","latestPrice":50.48,"preClose":50.48,"latestTime":"16:07 EDT","volume":15308,"amount":772747.84,"timestamp":1744920471689},"delay":0,"floatShares":46615360,"shares":47182862,"eps":-0.458541,"marketStatus":"Market Closed","change":0.93,"latestTime":"04-17 16:00:00 EDT","open":49.91,"high":50.98,"low":49.725,"amount":20420541.548092,"amplitude":0.025328,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.458541,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":49.55,"dividendRate":0.031696,"preHourTrading":{"tag":"盘前","latestPrice":49.55,"preClose":49.55,"latestTime":"08:02 EDT","volume":10,"amount":492.04998,"timestamp":1744891342185},"postHourTrading":{"tag":"盘后","latestPrice":50.48,"preClose":50.48,"latestTime":"16:07 EDT","volume":15308,"amount":772747.84,"timestamp":1744920471689},"volumeRatio":0.672300055897583,"impliedVol":0.5279,"impliedVolPercentile":0.9562},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASH\",,,,,undefined,":{"symbol":"ASH","floatShares":46615360,"roa":"1.94%","roe":"0.18%","lyrEps":3.448979,"volumeRatio":0.672300055897583,"shares":47182862,"dividePrice":1.6,"high":50.98,"amplitude":0.025328,"preClose":49.55,"low":49.725,"week52Low":45.21,"pbRate":"0.92","psRate":"1.16","week52High":102.5,"institutionHeld":0.8513,"latestPrice":50.48,"eps":-0.458541,"divideRate":0.031696,"volume":404291,"delay":0,"ttmEps":-0.458541,"open":49.91,"prevYearClose":71.46,"prevWeekClose":50.51,"prevMonthClose":59.29,"prevQuarterClose":59.29,"fiveDayClose":48.59,"twentyDayClose":55.87,"sixtyDayClose":70.63,"earningDate":1745942400000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASH\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2490583487","title":"DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2490583487","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490583487?lang=en_us&edition=fundamental","pubTime":"2024-12-09 00:21","pubTimestamp":1733674860,"startTime":"0","endTime":"0","summary":"First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study. SAN DIEGO, Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson  today announced data fromthe Phase 3 AQUILA study showing that DARZALEX FASPRO  significantly delayed progression from high-risk smoldering multiple myeloma  to active multiple myeloma  and extended overall survival compared to the current standard of care of active monitoring.1The data were presented for the first time as an oral presentation at the 2024 American Society of Hematology  Annual Meeting , as part of the Press Program and were selected for the Best of ASH session.Additionally, patients who received DARZALEX FASPRO saw a higher overall response rate of 63.4 percent compared to 2.0 percent with active monitoring . Median time to first-line MM treatment was not reached for patients receiving DARZALEX FASPRO compared to","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6_sqnqYDdG6MlUbMNpXtxA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/98a69363438bceaa4d51faba78e29c5c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6_sqnqYDdG6MlUbMNpXtxA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/98a69363438bceaa4d51faba78e29c5c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/darzalex-faspro-daratumumab-hyaluronidase-fihj-162100357.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/darzalex-faspro-daratumumab-hyaluronidase-fihj-162100357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1674673428.USD","IE00BFTCPJ56.SGD","IE000M9KFDE8.USD","LU1585245621.USD","BK4592","LU1935042991.SGD","BK4588","LU0345769631.USD","LU1267930813.SGD","LU1929549753.HKD","LU2347655156.SGD","BK4504","LU1221951129.SGD","LU1244550221.USD","IE0002141913.USD","LU1430594728.SGD","LU1280957306.USD","BK4568","LU0203345920.USD","BK4572","PFS","IE00B19Z3581.USD","BK4211","LU1261432733.SGD","BK4585","BK4109","LU1878469433.USD","LU0466842654.USD","AL","SG9999001440.SGD","IE00BSNM7G36.USD","SPE","LU1059921491.USD","JNJ","IE00B7SZLL34.SGD","IE00BGHQF631.EUR","PI","IE00B42XCP33.USD","BK4141","LU1894683264.USD","LU1674673691.USD","SG9999002232.USD","BK4532","LU1074936037.SGD","LU0889566641.SGD","ASH","LU0289739699.SGD","BK4007","LU1032955483.USD"],"gpt_icon":0},{"id":"2490573709","title":"Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2490573709","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490573709?lang=en_us&edition=fundamental","pubTime":"2024-12-09 00:00","pubTimestamp":1733673600,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/08/2993388/0/en/Investigational-Epcoritamab-DuoBody-CD3xCD20-Monotherapy-Achieves-High-Overall-and-Complete-Response-Rates-in-Clinical-Trial-of-Patients-With-Relapsed-or-Refractory-R-R-Chronic-Lym.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RS","BK4011","BK4109","BK4139","BK4161","BK4561","EXP","LU2463526074.USD","ASH","BK4195","IE00BLDYK493.USD","CR","OPT","BK4211","BK4006","PFS","IE00B64QTZ34.USD","OS","BK4097"],"gpt_icon":0},{"id":"2490173091","title":"Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490173091","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490173091?lang=en_us&edition=fundamental","pubTime":"2024-12-09 00:00","pubTimestamp":1733673600,"startTime":"0","endTime":"0","summary":"CALQUENCE plus venetoclax with obinutuzumab reduced the risk of disease progression or death by 58% versus standard of care in this setting. CALQUENCE plus venetoclax poised to become first all-oral fixed-duration regimen of a second-generation BTK inhibitor plus venetoclax in 1st-line CLL. WILMINGTON, Del., December 08, 2024----Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s CALQUENCE  in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival  compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia .Both investigational arms demonstrated durable responses, with estimated 36-month PFS rates of 76.5% for CALQUENCE plus venetoclax and","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/usNgcZHCkTNCwRfSrRhYiQ--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/00ecf8619a060c319ac3ba209f6673b7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/usNgcZHCkTNCwRfSrRhYiQ--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/00ecf8619a060c319ac3ba209f6673b7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fixed-duration-calquence-plus-venetoclax-160000602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFS","BK4097","BK4211","BK4195","III","LU0109394709.USD","PML","BK4585","LU0889565916.HKD","LU2236285917.USD","BK4109","LU2456880835.USD","TLS","LU2462157665.USD","ASH","BK4134","BK4007","LU2417539215.USD","BK4588","LU0320765992.SGD","LU1829250122.USD","BK4568","AZN","OS","LU2463526074.USD"],"gpt_icon":0},{"id":"2489772292","title":"Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions","url":"https://stock-news.laohu8.com/highlight/detail?id=2489772292","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489772292?lang=en_us&edition=fundamental","pubTime":"2024-12-08 07:30","pubTimestamp":1733614200,"startTime":"0","endTime":"0","summary":"New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment of t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/07/2993357/0/en/Adaptive-Biotechnologies-Announces-New-Data-at-the-66th-ASH-Annual-Meeting-Highlighting-Advances-in-MRD-Testing-with-clonoSEQ-and-Its-Impact-on-Blood-Cancer-Treatment-Decisions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4161","CR","ASH","BK4109","BK4097","SR","LU2463526074.USD","BK4197"],"gpt_icon":0},{"id":"2489227271","title":"Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2489227271","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489227271?lang=en_us&edition=fundamental","pubTime":"2024-12-08 01:30","pubTimestamp":1733592600,"startTime":"0","endTime":"0","summary":"Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied.96% of patients received an infusion of fresh, fit, stem-like, early memory CD19 CAR T-cell therapy with a median vein-to-vein time of seven days, avoiding the need for cryopreservation and bridging therapy.These data reinforce the potential of Galapagos’ decentralized cell therapy manufacturing platform to deliver fresh, fit cells, fast, driving positive patient outcomes.High objective response rates  and complete response rates  were observed in the pooled Phase 1 and Phase 2 efficac","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aIgoKEpCU4miJJgLiiqeLg--~B/aD05Mzg7dz01MDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/27744832f947e91d201e1a07d1998d59","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aIgoKEpCU4miJJgLiiqeLg--~B/aD05Mzg7dz01MDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/27744832f947e91d201e1a07d1998d59"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galapagos-announces-encouraging-results-ongoing-173000246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4588","BK4094","FL","BK4022","BK4230","BK4109","ASH","BK4585","GLPG","LU2463526074.USD","CAR"],"gpt_icon":0},{"id":"2489898222","title":"Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2489898222","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489898222?lang=en_us&edition=fundamental","pubTime":"2024-12-08 01:00","pubTimestamp":1733590800,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  07, 2024  (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commerci","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/07/2993346/0/en/Y-mAbs-Presents-SADA-Platform-Preclinical-Data-and-Trial-in-Progress-Posters-at-the-2024-American-Society-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","UK","BK4205","LU2463526074.USD","BK4528","PRGS","BK4233","BK4097","ASH","BK4107","BK4109","BK4117","LU2065732104.USD"],"gpt_icon":0},{"id":"2489227859","title":"Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2489227859","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489227859?lang=en_us&edition=fundamental","pubTime":"2024-12-08 01:00","pubTimestamp":1733590800,"startTime":"0","endTime":"0","summary":"Treatment effects sustained through long-term follow-up of beyond 10 years in the earliest treated patients (n=2); 81% of participants have >5 years of follow-up. SOMERVILLE, Mass., December 07, 2024----bluebird bio, Inc.  today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene autotemcel  in clinical studies. The data was presented today at the 66th American Society of Hematology  Annual Meeting and Exposition.Of 63 patients, 52  achieved TI. All except one patient maintained TI through last follow-up. The median weighted average hemoglobin during TI was 10.2 mg/dL for Phase 1/2 studies and 11.2 mg/dL for Phase 3 studies. Achievement and maintenance of TI and median weighted average hemoglobin were similar across ages and genotypes.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8ZUGtl8DTKBazVcDWb2XNw--~B/aD0zNDg7dz0xMzk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0582dcb436ed33e82e9f1b8a5182c238","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8ZUGtl8DTKBazVcDWb2XNw--~B/aD0zNDg7dz0xMzk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0582dcb436ed33e82e9f1b8a5182c238"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/long-term-data-continue-support-170000508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU2463526074.USD","RBC","IE00BLDYK493.USD","LU2065731478.USD","BK4161","BK4109","BK4556","ASH","BK4578","IE00B64QTZ34.USD","BLUE"],"gpt_icon":0},{"id":"2489220997","title":"Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2489220997","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489220997?lang=en_us&edition=fundamental","pubTime":"2024-12-08 01:00","pubTimestamp":1733590800,"startTime":"0","endTime":"0","summary":"73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months. NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve  0-15 days post-administration being 5.8-fold greater than placebo-controls. In this multicenter, double-blind Phase 2 study, patients were randomized to receive one of three dose regimens of NKTR-255 or placebo intravenously starting 14 days after CAR-T infusion. In the fifteen-person clinical trial, the NKTR-255 combined treatment group demonstrated an improved CRR at six months, achieving 73% compared to 50% for the placebo, as assessed by a blinded independent central radiology review. Additionally, two patients treated with NKTR-255 converted from stable disease or partial response to complete responses at six months. No conversions from stable disease or partial response to complete response were observed in the placebo arm of the trial.\"This study is the first randomized trial demons","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rtboK12ORMgNOQ6pHWHlMg--~B/aD04Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/ed402d287488a53ce89b92f9b5ed2bb0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rtboK12ORMgNOQ6pHWHlMg--~B/aD04Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/ed402d287488a53ce89b92f9b5ed2bb0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-therapeutics-announces-nktr-255-170000373.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-announces-nktr-255-170000373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAR","BK4109","CSF","BK4230","LU2463526074.USD","ASH","BK4022","NKTR","BK4007"],"gpt_icon":0},{"id":"2489224894","title":"Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2489224894","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489224894?lang=en_us&edition=fundamental","pubTime":"2024-12-08 00:30","pubTimestamp":1733589000,"startTime":"0","endTime":"0","summary":"All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Post-BEAM-101 Treatment Initial Safety Profile Co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/07/2993343/0/en/Beam-Therapeutics-Announces-New-Data-from-BEACON-Phase-1-2-Clinical-Trial-of-BEAM-101-in-Sickle-Cell-Disease-at-American-Society-of-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU2463526074.USD","BK4556","ASH","AFG","BK4505","HSCT","BK4585","BK4588","BK4139","BK4109","BK4117","BEAM","BK4107","SCD"],"gpt_icon":0},{"id":"2489222687","title":"BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489222687","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489222687?lang=en_us&edition=fundamental","pubTime":"2024-12-07 23:00","pubTimestamp":1733583600,"startTime":"0","endTime":"0","summary":"Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%. THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ -- Amgen  today announcednew data demonstrating that adding BLINCYTO  to chemotherapy significantly improves disease-free survival  in newly diagnosed pediatric patients with National Cancer Institute  standard risk  B-cell acute lymphoblastic leukemia  of average or higher risk of relapse. The data are from a Phase 3 study  conducted by the Children's Oncology Group. The results were simultaneously publishedin the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8, at 2 p.m. PT at the 66th American Society of Hematology  Annual Meeting & Exposition in San Diego.The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/blincyto-blinatumomab-added-chemotherapy-significantly-150000076.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/blincyto-blinatumomab-added-chemotherapy-significantly-150000076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","IE00B19Z3B42.SGD","LU0122379950.USD","AMGN","CLS","IE00BJJMRZ35.SGD","TLS","NCI","AST","LU1165135440.EUR","IE0031619046.USD","BK4533","LU2360107671.USD","LU0170899867.USD","BK4166","LU0985320562.USD","LU2125910500.SGD","BK4006","LU1059921491.USD","MAS","BK4139","ASH","DFS","IE00B19Z3581.USD","LU1571399168.USD","CNS","CELL","IE00B2B36J28.USD","BK4135","LU1023059063.AUD","LU1861220207.SGD","BK4097","ALL","LU0106831901.USD","LU1861217088.USD","IE00BFTCPJ56.SGD","LU1596574779.USD","SR","BK4156","LU1261432733.SGD","LU1620156130.USD","IE00B19Z4B17.USD","HR","ALT","BK4196","IE0002141913.USD","CRS","CI","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2488193601","title":"X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2488193601","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488193601?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:00","pubTimestamp":1733317200,"startTime":"0","endTime":"0","summary":"Pivotal Phase 3 4WARD clinical trial is evaluating use of oral mavorixafor as monotherapy and in combination with injectable G-CSFBOSTON, Dec.  04, 2024  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/04/2991427/0/en/X4-Pharmaceuticals-to-Present-Trial-in-Progress-Poster-on-Phase-3-Study-of-Mavorixafor-in-Chronic-Neutropenia-at-66th-ASH-Annual-Meeting-Exposition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","LU2463526074.USD","ASH","PRGS","BK4097","BK4109","CN"],"gpt_icon":0},{"id":"2488971924","title":"BLRX: Ayrmid Assumes Commercialization Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2488971924","media":"Zacks Small Cap Research","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488971924?lang=en_us&edition=fundamental","pubTime":"2024-12-04 00:11","pubTimestamp":1733242260,"startTime":"0","endTime":"0","summary":"A few days prior to its third quarter earnings report, BioLineRx Ltd.  announced a commercialization agreement with Ayrmid Ltd. and its subsidiary Gamida Cell Ltd. BioLineRx will grant Ayrmid rights to commercialize Aphexda  across all indications except in solid tumors and in all territories except Asia. The arrangement will provide a $10 million upfront payment to BioLineRx, royalties ranging from 18% to 23% and the potential for $87 million in commercial milestones. After a transition period, BioLineRx’ expenses are expected to decline by about 70% as the company reverts to a research and development firm.The announcement of the arrangement with Ayrmid was followed by the third quarter earnings report where total revenues reached $4.9 million and net loss was  million. Aphexda revenues were down sequentially to $1.7 million and lower than expected expenses across the board, especially sales and marketing led to the less severe-than-expected loss which was about 60% of what we had fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/blrx-ayrmid-assumes-commercialization-efforts-161100452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU1481011911.USD","LU1064131342.USD","LU2264538146.SGD","LU2505996681.GBP","BLK","LU0731783048.USD","LU1291159041.SGD","LU0772969993.USD","ASH","IE00B3PB1722.GBP","IE00BVYPNV92.GBP","LU1280957306.USD","BK4533","LU0070302665.USD","BK4588","IE00B3QW5Z07.USD","LU1481011671.HKD","IE00B42XCP33.USD","BK4504","LU0980610538.SGD","BK4109","LU0648001328.SGD","IE00B64PRP62.GBP","LU0320765489.SGD","LU2463526074.USD","LU2430703251.USD","IE00BVYPNW00.USD","BK4581","LU1988902786.USD","LU1670628061.USD","LU2430703095.HKD","LU0742537680.HKD","BLRX","LU0208291251.USD","LU1074936037.SGD","BK4585","IE00BDGV0183.EUR","BK4535","LU1599440770.SGD","BK4135","LU0130102774.USD","LU1989771016.USD","LU2430703178.SGD","IE00BGHQF748.EUR","LU0731783394.SGD","LU1201861249.SGD","BK4567","BK4534","IE00BGHQF631.EUR"],"gpt_icon":1},{"id":"2488945710","title":"INEOS Enterprises to sell composites business for about $1.79 bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2488945710","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488945710?lang=en_us&edition=fundamental","pubTime":"2024-12-03 22:43","pubTimestamp":1733237037,"startTime":"0","endTime":"0","summary":"INEOS Enterprises to sell composites business for about $1.79 blnDec 3  - Chemical products maker INEOS Enterprises said on Tuesday it would sell INEOS Composites, maker of specialty composite resins, for an estimated 1.7 billion euros  at completion, to investment fund KPS Capital Partners.INEOS Enterprises, part of British billionaire Jim Ratcliffe-owned INEOS, said the composites business had combined sales of more than 800 million euros per year and a workforce of about 900 employees across 17 sites in Europe, North and South America, Asia and the Middle East.  INEOS Composites sells a broad range of resins that helps products with corrosion and scratch resistance, fire retardancy, among other things.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nL3N3N411T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","BK4109","ASH"],"gpt_icon":0},{"id":"2488914703","title":"Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2488914703","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488914703?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:49","pubTimestamp":1733230140,"startTime":"0","endTime":"0","summary":"Data showcased at SABCS and ASH reflect progress and growth of Jazz's research and development in oncology and demonstrate ongoing efforts to redefine what is possible for cancer treatment. DUBLIN, Dec. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc  today announced that the Company and its partners will present two abstracts at the 2024 San Antonio Breast Cancer Symposium  fromDecember 10-13 and 13 abstracts at the 66th AnnualAmerican Society of Hematology Annual Meeting fromDecember 7-10.A trial-in-progress poster presentation at SABCS outlines the trial design of the ongoing Phase 3 EmpowHER-303 trial , which is evaluating the efficacy and safety of Ziihera  vs trastuzumab with chemotherapy in patients with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, trastuzumab deruxtecan. New data from a Phase 1b/2 studyof zanidatamab plus evorpacept in patients with pre-treated HER2-positive and HER2-low metastatic breast cancer will be featured as a pos","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/z9XurA.79rXKO7Hh4sqh5w--~B/aD02Njt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/095ab4a08f01b2302a3f1586ae50e031","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/z9XurA.79rXKO7Hh4sqh5w--~B/aD02Njt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/095ab4a08f01b2302a3f1586ae50e031"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-present-advancements-solid-124900646.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-present-advancements-solid-124900646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4547","GO","HSCT","BK4532","BK4123","BTC","PST","CDC","LU0471298777.SGD","BK4107","BK4132","LU0385154629.USD","BK4113","LU0320765992.SGD","BK4585","BK4533","LU2463526074.USD","JAZZ","LU0889565916.HKD","AFG","BK4007","ASH","BK4109","HMA","NGS","LU0109394709.USD","VOD","BK4117","BK4179"],"gpt_icon":1},{"id":"2488391462","title":"Adaptive Biotechnologies announces 65 abstracts to be presented at ASH meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2488391462","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488391462?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:40","pubTimestamp":1733229616,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (ADPT) announced that its next-generation sequencing-based clonoSEQ test for measurable residual disease assessment will b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-announces-65-abstracts-to-be-presented-at-ash-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-announces-65-abstracts-to-be-presented-at-ash-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2463526074.USD","ASH","BK4109","BK4121","ADPT"],"gpt_icon":0},{"id":"2488116319","title":"Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2488116319","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488116319?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:30","pubTimestamp":1733229000,"startTime":"0","endTime":"0","summary":"SEATTLE, Dec.  03, 2024  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sy","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/03/2990477/0/en/Adaptive-Biotechnologies-Announces-Over-65-Abstracts-Featuring-clonoSEQ-MRD-Testing-Across-a-Range-of-Blood-Cancers-to-be-Presented-at-the-66th-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4533","LU2355687059.USD","LU0985320562.USD","ALL","LU1571399168.USD","LU2463526074.USD","ASH","BK4179","LU1699723380.USD","NGS","BK4107","BK4588","BK4109"],"gpt_icon":0},{"id":"2488913196","title":"Innate Pharma SA’s Innovations Spotlighted at ASH 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2488913196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488913196?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:28","pubTimestamp":1733225286,"startTime":"0","endTime":"0","summary":"Innate Pharma SA (FR:IPH) has released an update. Innate Pharma SA has announced its selection for the 2024 ASH Annual Meeting, highlighting their ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innate-pharma-sas-innovations-spotlighted-at-ash-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innate-pharma-sas-innovations-spotlighted-at-ash-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHA","BK4139","LU2463526074.USD","ASH","BK4109"],"gpt_icon":0},{"id":"2488965711","title":"Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2488965711","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488965711?lang=en_us&edition=fundamental","pubTime":"2024-12-03 14:00","pubTimestamp":1733205600,"startTime":"0","endTime":"0","summary":"Innate Pharma SA   today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET asset, have been selected for the American Society of hematology  Annual Meeting.\"We are proud of the progress being made across our multiple programs, including our lead proprietary asset lacutamab and the multi-specific NK cell engagers from our ANKET platform,\" commented Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma. \"We look forward to presenting data supporting the advancement of our programs at the upcoming ASH 2024 as we move closer to our goal of delivering new treatment options for patients with high unmet medical needs.\". More information can be found on the ASH website.KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up 90% of patients with certain aggressive CTCL subtypes, in particular, S","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XyaUg1BiBmXltBH_9EF1pw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ec57b53d11fe7a69c2ae1c6568781860","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XyaUg1BiBmXltBH_9EF1pw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ec57b53d11fe7a69c2ae1c6568781860"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/innate-pharma-highlights-abstracts-selected-060000004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","ADC","ASH","BK4109","BK4139","BK4231","IPHA","IPHYF","LU2463526074.USD"],"gpt_icon":0},{"id":"2488957969","title":"Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2488957969","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488957969?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:45","pubTimestamp":1733147100,"startTime":"0","endTime":"0","summary":"-- Presentations Highlight Progress in Late-Stage Development of Lead MASP-3 Inhibitor Zaltenibart --. SEATTLE, December 02, 2024----Omeros Corporation  today announced that two abstracts directed to zaltenibart , Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 66th Annual Meeting of the American Society of Hematology , to be held December 7-10, 2024 in San Diego. The zaltenibart abstracts are directed to the treatment of paroxysmal nocturnal hemoglobinuria , a rare, life-threatening hematological disorder. Enrollment for the zaltenibart Phase 3 clinical trials in PNH is expected to open in early 2025.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/X8rOnvPYPdwEug9.Eg0dYw--~B/aD0zNDI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8ddfa7aea6799bf043d8ad6e529895be","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/X8rOnvPYPdwEug9.Eg0dYw--~B/aD0zNDI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8ddfa7aea6799bf043d8ad6e529895be"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/omeros-corporation-announces-upcoming-presentations-134500315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4109","ASH","BK4007","OMER","LU2463526074.USD"],"gpt_icon":0},{"id":"2488957110","title":"Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers at ESMO Asia, SABCS and ASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2488957110","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488957110?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:00","pubTimestamp":1733144400,"startTime":"0","endTime":"0","summary":"Three late-breaking presentations across lung and breast cancer trials of three DXd ADCs to be showcased. Science & Technology Day to provide overview of data and strategy across Daiichi Sankyo R&D pipeline. BASKING RIDGE, N.J., December 02, 2024----Daiichi Sankyo  will present new clinical research across its oncology portfolio with more than 45 abstracts in multiple types of solid and blood cancers at the 2024 ESMO Asia Congress , San Antonio Breast Cancer Symposium  and American Society of Hematology  Annual Meeting prior to its Science & Technology Day.\"Important updates in difficult-to-treat cancers including lung, breast, gastric and biliary tract cancer as well as acute myeloid leukemia and peripheral T-cell lymphoma will be highlighted at these upcoming meetings,\" said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. \"We continue to make important progress with our approved and pipeline medicines with the goal of changing the standard of care across a wide range of cancers.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cY88dbmI1XxsMFQZFBouAA--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/833a7ce6e6a3c8b494d8cbffdb4e6c79","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cY88dbmI1XxsMFQZFBouAA--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/833a7ce6e6a3c8b494d8cbffdb4e6c79"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/daiichi-sankyo-highlights-progress-across-130000400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4162","IHC","CST","PBD","DSNKY","BK4109","DSKYF","BK4007","LU2065732104.USD","LU2463526074.USD","PST","PRGS","ASH","BK4097"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASH\",params:#limit:5,,,undefined,":[{"date":"2025-04-30","symbol":"ASH","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":1.14,"defaultRemindTime":1746043200000,"name":null,"time":"Post Market","dateTimestamp":1745985600000,"actualEps":null},{"date":"2025-02-28","symbol":"ASH","amount":0.405,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-01","defaultRemindTime":1740753000000,"name":"亚什兰","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-15","payableDate":"2025-03-01","currency":"USD","dateTimestamp":1740718800000,"payDate":"2025-03-15"},{"market":"US","date":"2025-01-28","symbol":"ASH","fiscalQuarterEnding":"2024/12","expectedEps":0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738040400000,"reportTimeType":"post","actualEps":0.28},{"date":"2024-11-29","symbol":"ASH","amount":0.405,"announcedDate":"2024-11-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-01","defaultRemindTime":1732890600000,"name":"亚什兰","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-15","payableDate":"2024-12-01","currency":"USD","dateTimestamp":1732856400000,"payDate":"2024-12-15"},{"market":"US","date":"2024-11-06","symbol":"ASH","fiscalQuarterEnding":"2024/09","expectedEps":1.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"post","actualEps":1.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASH\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-27","recordDate":"2015-05-29","paymentDate":"2015-06-15","value":0.39,"currency":"USD"},{"executeDate":"2015-08-19","recordDate":"2015-08-21","paymentDate":"2015-09-15","value":0.39,"currency":"USD"},{"executeDate":"2015-11-27","recordDate":"2015-12-01","paymentDate":"2015-12-15","value":0.39,"currency":"USD"},{"executeDate":"2016-02-17","recordDate":"2016-02-19","paymentDate":"2016-03-15","value":0.39,"currency":"USD"},{"executeDate":"2016-06-01","recordDate":"2016-06-03","paymentDate":"2016-06-15","value":0.39,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.4545,"hold":0.2727,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4545,"analysts":11,"updateTime":1743048000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ASH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ASH","date":"2025-04-17","current":-106.268673,"percent":0.042184,"low":-152.607239,"twenty":-10.617545,"median":17.86146,"eighty":27.96106,"high":41.666396,"avg":3.080485,"sd":37.618835,"marketCap":2337910812},"quantilePoints":[{"date":"2020-04-24","current":5.830102,"twenty":10.902122,"median":16.855926,"eighty":45.060758,"marketCap":3410609559},{"date":"2020-05-01","current":6.059763,"twenty":10.78415,"median":16.855926,"eighty":45.060758,"marketCap":3544961429},{"date":"2020-05-08","current":-51.569829,"twenty":10.709199,"median":16.855926,"eighty":45.060758,"marketCap":3764597548},{"date":"2020-05-15","current":-48.919702,"twenty":10.615504,"median":16.855926,"eighty":45.060758,"marketCap":3571138223},{"date":"2020-05-22","current":-52.571909,"twenty":9.138439,"median":16.855926,"eighty":45.060758,"marketCap":3837749355},{"date":"2020-05-29","current":-55.619556,"twenty":9.120788,"median":16.855926,"eighty":45.060758,"marketCap":4060227579},{"date":"2020-06-05","current":-59.636156,"twenty":9.07954,"median":16.855926,"eighty":45.060758,"marketCap":4353439368},{"date":"2020-06-12","current":-55.13922,"twenty":9.032533,"median":16.855926,"eighty":45.060758,"marketCap":4025163076},{"date":"2020-06-19","current":-56.936338,"twenty":8.983635,"median":16.855926,"eighty":45.060758,"marketCap":4156352681},{"date":"2020-06-26","current":-55.08953,"twenty":8.930444,"median":16.855926,"eighty":45.060758,"marketCap":4021535714},{"date":"2020-07-02","current":-57.723095,"twenty":8.872607,"median":16.855926,"eighty":45.060758,"marketCap":4213785918},{"date":"2020-07-10","current":-57.093689,"twenty":8.675995,"median":16.855926,"eighty":45.060758,"marketCap":4167839328},{"date":"2020-07-17","current":-63.354616,"twenty":8.557057,"median":16.855926,"eighty":45.060758,"marketCap":4624886983},{"date":"2020-07-24","current":-64.439512,"twenty":8.367293,"median":16.855926,"eighty":45.060758,"marketCap":4704084394},{"date":"2020-07-31","current":-44.748169,"twenty":8.317859,"median":16.855926,"eighty":45.060758,"marketCap":4564313264},{"date":"2020-08-07","current":-47.060277,"twenty":8.104676,"median":16.855926,"eighty":45.060758,"marketCap":4800148210},{"date":"2020-08-14","current":-45.655227,"twenty":7.849302,"median":16.855926,"eighty":45.060758,"marketCap":4656833127},{"date":"2020-08-21","current":-44.599957,"twenty":7.651738,"median":16.855926,"eighty":45.060758,"marketCap":4549195639},{"date":"2020-08-28","current":-44.718527,"twenty":7.25977,"median":16.855926,"eighty":45.060758,"marketCap":4561289739},{"date":"2020-09-04","current":-44.196821,"twenty":6.363575,"median":16.855926,"eighty":45.060758,"marketCap":4508075700},{"date":"2020-09-11","current":-43.260121,"twenty":6.075417,"median":16.855926,"eighty":45.060758,"marketCap":4412532312},{"date":"2020-09-18","current":-42.133709,"twenty":5.834015,"median":16.855926,"eighty":45.060758,"marketCap":4297638363},{"date":"2020-09-25","current":-41.013227,"twenty":5.699102,"median":16.855926,"eighty":45.060758,"marketCap":4183349120},{"date":"2020-10-02","current":-42.044782,"twenty":5.471088,"median":16.855926,"eighty":45.060758,"marketCap":4288567789},{"date":"2020-10-09","current":-44.101965,"twenty":5.216092,"median":16.855926,"eighty":45.060758,"marketCap":4498400420},{"date":"2020-10-16","current":-45.258019,"twenty":4.885092,"median":16.855926,"eighty":45.060758,"marketCap":4616317893},{"date":"2020-10-23","current":-44.754098,"twenty":4.479735,"median":16.855926,"eighty":45.060758,"marketCap":4564917969},{"date":"2020-10-30","current":-41.363007,"twenty":-40.555548,"median":16.855926,"eighty":45.060758,"marketCap":4219026715},{"date":"2020-11-06","current":-44.754098,"twenty":-41.328622,"median":16.855926,"eighty":45.060758,"marketCap":4564917969},{"date":"2020-11-13","current":-9.712181,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4933788013},{"date":"2020-11-20","current":-9.201515,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4674369572},{"date":"2020-11-27","current":-9.108247,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4626989343},{"date":"2020-12-04","current":-8.938913,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4540967808},{"date":"2020-12-11","current":-9.025329,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4584867159},{"date":"2020-12-18","current":-9.373926,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4761954621},{"date":"2020-12-24","current":-9.457494,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4804407095},{"date":"2020-12-31","current":-9.455107,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4803194167},{"date":"2021-01-08","current":-10.356446,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":5261074419},{"date":"2021-01-15","current":-10.145138,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":5153730307},{"date":"2021-01-22","current":-10.225125,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":5194363389},{"date":"2021-01-29","current":-9.549419,"twenty":-41.685517,"median":16.84568,"eighty":45.060758,"marketCap":4851104816},{"date":"2021-02-05","current":-10.650636,"twenty":-41.685517,"median":16.798842,"eighty":45.060758,"marketCap":5154907958},{"date":"2021-02-12","current":-10.819853,"twenty":-41.685517,"median":16.763713,"eighty":45.060758,"marketCap":5236808932},{"date":"2021-02-19","current":-10.931411,"twenty":-41.685517,"median":16.727121,"eighty":45.060758,"marketCap":5290802907},{"date":"2021-02-26","current":-10.544092,"twenty":-41.685517,"median":16.708151,"eighty":45.060758,"marketCap":5103340678},{"date":"2021-03-05","current":-10.893807,"twenty":-41.766144,"median":16.655852,"eighty":45.067329,"marketCap":5272602691},{"date":"2021-03-12","current":-11.366361,"twenty":-41.766144,"median":16.626772,"eighty":45.067329,"marketCap":5501318743},{"date":"2021-03-19","current":-11.074305,"twenty":-41.766144,"median":16.605449,"eighty":45.067329,"marketCap":5359963729},{"date":"2021-03-26","current":-11.298674,"twenty":-41.685517,"median":16.565507,"eighty":45.060758,"marketCap":5468558354},{"date":"2021-04-01","current":-11.32625,"twenty":-41.685517,"median":16.544159,"eighty":45.032615,"marketCap":5481905179},{"date":"2021-04-09","current":-11.130711,"twenty":-41.766144,"median":16.513421,"eighty":45.025182,"marketCap":5387264054},{"date":"2021-04-16","current":-11.373882,"twenty":-41.766144,"median":16.49824,"eighty":44.88663,"marketCap":5504958787},{"date":"2021-04-23","current":-11.615799,"twenty":-41.766144,"median":16.458163,"eighty":44.798223,"marketCap":5622046845},{"date":"2021-04-30","current":37.652621,"twenty":-41.766144,"median":16.458163,"eighty":44.763306,"marketCap":5233714269},{"date":"2021-05-07","current":38.556703,"twenty":-41.766144,"median":16.48927,"eighty":44.763306,"marketCap":5359381692},{"date":"2021-05-14","current":38.897371,"twenty":-41.766144,"median":16.508117,"eighty":44.763306,"marketCap":5406734634},{"date":"2021-05-21","current":38.897371,"twenty":-41.766144,"median":16.532217,"eighty":44.763306,"marketCap":5406734634},{"date":"2021-05-28","current":41.421813,"twenty":-41.766144,"median":16.539302,"eighty":44.763306,"marketCap":5757632076},{"date":"2021-06-04","current":41.177231,"twenty":-41.766144,"median":16.551203,"eighty":44.763306,"marketCap":5723635092},{"date":"2021-06-11","current":40.923913,"twenty":-41.766144,"median":16.551203,"eighty":44.763306,"marketCap":5688423930},{"date":"2021-06-18","current":38.067538,"twenty":-41.766144,"median":16.551203,"eighty":44.763306,"marketCap":5291387724},{"date":"2021-06-25","current":38.72267,"twenty":-41.766144,"median":16.559996,"eighty":44.763306,"marketCap":5382451074},{"date":"2021-07-02","current":38.32959,"twenty":-41.766144,"median":16.589527,"eighty":44.763306,"marketCap":5327813064},{"date":"2021-07-09","current":38.399471,"twenty":-41.766144,"median":16.609898,"eighty":44.763306,"marketCap":5337526488},{"date":"2021-07-16","current":37.713766,"twenty":-41.766144,"median":16.609898,"eighty":44.763306,"marketCap":5242213515},{"date":"2021-07-23","current":38.233504,"twenty":-41.766144,"median":16.609898,"eighty":44.763306,"marketCap":5314457106},{"date":"2021-07-30","current":28.544675,"twenty":-41.766144,"median":16.63409,"eighty":44.763306,"marketCap":5166586254},{"date":"2021-08-06","current":28.329928,"twenty":-41.766144,"median":16.642592,"eighty":44.763306,"marketCap":5127716909},{"date":"2021-08-13","current":29.118455,"twenty":-41.766144,"median":16.707431,"eighty":44.763306,"marketCap":5270440286},{"date":"2021-08-20","current":28.051427,"twenty":-41.766144,"median":16.798988,"eighty":44.763306,"marketCap":5077308227},{"date":"2021-08-27","current":29.259383,"twenty":-41.766144,"median":16.876011,"eighty":44.763306,"marketCap":5295948294},{"date":"2021-09-03","current":31.51759,"twenty":-41.685517,"median":16.928602,"eighty":44.762757,"marketCap":5704683753},{"date":"2021-09-10","current":31.051184,"twenty":-41.685517,"median":16.94157,"eighty":44.762757,"marketCap":5620264394},{"date":"2021-09-17","current":30.272724,"twenty":-41.685517,"median":16.987677,"eighty":44.762757,"marketCap":5479363017},{"date":"2021-09-24","current":31.121649,"twenty":-41.685517,"median":16.987677,"eighty":44.762757,"marketCap":5633018398},{"date":"2021-10-01","current":30.59149,"twenty":-41.685517,"median":19.684212,"eighty":44.762757,"marketCap":5537059701},{"date":"2021-10-08","current":31.071317,"twenty":-41.685517,"median":19.787677,"eighty":44.762757,"marketCap":5623908395},{"date":"2021-10-15","current":32.124923,"twenty":-41.685517,"median":19.83941,"eighty":44.762757,"marketCap":5814611120},{"date":"2021-10-22","current":32.826209,"twenty":-41.685517,"median":19.917009,"eighty":44.762757,"marketCap":5941543826},{"date":"2021-10-29","current":32.21552,"twenty":-41.604889,"median":19.999764,"eighty":44.762207,"marketCap":5831009125},{"date":"2021-11-05","current":32.916806,"twenty":-41.604889,"median":20.15896,"eighty":44.762207,"marketCap":5957941831},{"date":"2021-11-12","current":29.342491,"twenty":-41.604889,"median":20.28364,"eighty":44.762207,"marketCap":6455347984},{"date":"2021-11-19","current":30.162391,"twenty":-41.604889,"median":20.500749,"eighty":44.762207,"marketCap":6635726039},{"date":"2021-11-26","current":26.923508,"twenty":-41.604889,"median":20.528215,"eighty":44.762207,"marketCap":5923171764},{"date":"2021-12-03","current":26.411959,"twenty":-41.604889,"median":20.552965,"eighty":44.762207,"marketCap":5810630932},{"date":"2021-12-10","current":27.165993,"twenty":-41.604889,"median":20.676932,"eighty":44.762207,"marketCap":5976518382},{"date":"2021-12-17","current":26.837476,"twenty":-41.604889,"median":20.708356,"eighty":44.762207,"marketCap":5904244736},{"date":"2021-12-23","current":26.982334,"twenty":-41.604889,"median":20.728755,"eighty":44.762207,"marketCap":5936113430},{"date":"2021-12-31","current":27.848893,"twenty":-41.604889,"median":20.764302,"eighty":44.762207,"marketCap":6126756513},{"date":"2022-01-07","current":26.876277,"twenty":-41.524262,"median":20.796751,"eighty":44.761658,"marketCap":5912780993},{"date":"2022-01-14","current":27.341891,"twenty":-41.524262,"median":20.868148,"eighty":44.761658,"marketCap":6015216083},{"date":"2022-01-21","current":25.013821,"twenty":-41.524262,"median":20.917445,"eighty":44.761658,"marketCap":5503040636},{"date":"2022-01-28","current":24.677544,"twenty":-41.524262,"median":20.980342,"eighty":44.761658,"marketCap":5429059738},{"date":"2022-02-04","current":25.572734,"twenty":-41.443634,"median":21.023702,"eighty":44.761108,"marketCap":5421419569},{"date":"2022-02-11","current":25.553938,"twenty":-41.443634,"median":21.065338,"eighty":44.761108,"marketCap":5417434905},{"date":"2022-02-18","current":25.494866,"twenty":-41.443634,"median":21.115412,"eighty":44.761108,"marketCap":5404911676},{"date":"2022-02-25","current":25.29617,"twenty":-41.443634,"median":21.157984,"eighty":44.761108,"marketCap":5362788089},{"date":"2022-03-04","current":23.572347,"twenty":-41.443634,"median":21.240692,"eighty":44.761108,"marketCap":4997337504},{"date":"2022-03-11","current":23.66901,"twenty":-41.443634,"median":21.332705,"eighty":44.761108,"marketCap":5017830061},{"date":"2022-03-18","current":25.352557,"twenty":-41.443634,"median":21.402701,"eighty":44.761108,"marketCap":5374742080},{"date":"2022-03-25","current":26.448071,"twenty":-41.443634,"median":21.507199,"eighty":44.761108,"marketCap":5606991049},{"date":"2022-04-01","current":26.544734,"twenty":-41.443634,"median":21.611248,"eighty":44.761108,"marketCap":5627483605},{"date":"2022-04-08","current":26.703154,"twenty":-41.443634,"median":21.681627,"eighty":44.761108,"marketCap":5661068628},{"date":"2022-04-14","current":28.520955,"twenty":-41.443634,"median":21.86021,"eighty":44.761108,"marketCap":6046442530},{"date":"2022-04-22","current":27.734226,"twenty":-41.443634,"median":22.114023,"eighty":44.761108,"marketCap":5879655893},{"date":"2022-04-29","current":5.98168,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5724467780},{"date":"2022-05-06","current":5.79477,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5545595204},{"date":"2022-05-13","current":5.627805,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5385809640},{"date":"2022-05-20","current":5.695617,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5450705483},{"date":"2022-05-27","current":6.155649,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5890955748},{"date":"2022-06-03","current":6.053281,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5792989652},{"date":"2022-06-10","current":5.809521,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5559711268},{"date":"2022-06-17","current":5.398352,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5166223136},{"date":"2022-06-24","current":5.835537,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5584608729},{"date":"2022-07-01","current":5.86325,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5611129938},{"date":"2022-07-08","current":5.737128,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5490431377},{"date":"2022-07-15","current":5.58499,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5344835356},{"date":"2022-07-22","current":5.922634,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5667961098},{"date":"2022-07-29","current":5.951187,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5439385116},{"date":"2022-08-05","current":6.14725,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5618586516},{"date":"2022-08-12","current":6.304219,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5762055916},{"date":"2022-08-19","current":6.275787,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5736069006},{"date":"2022-08-26","current":6.098679,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5574192212},{"date":"2022-09-02","current":5.884253,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5378207598},{"date":"2022-09-09","current":6.054846,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5534129059},{"date":"2022-09-16","current":5.848121,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5345182567},{"date":"2022-09-23","current":5.752755,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5258018139},{"date":"2022-09-30","current":5.625403,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5141618438},{"date":"2022-10-07","current":5.617703,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5134580316},{"date":"2022-10-14","current":5.641396,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5156236075},{"date":"2022-10-21","current":5.922755,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5413398206},{"date":"2022-10-28","current":6.27401,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5734444824},{"date":"2022-11-04","current":5.909724,"twenty":-41.524262,"median":21.695313,"eighty":44.761658,"marketCap":5401487538},{"date":"2022-11-11","current":6.292902,"twenty":-41.524262,"median":21.556282,"eighty":44.761658,"marketCap":5833519919},{"date":"2022-11-18","current":6.534105,"twenty":-41.524262,"median":9.134384,"eighty":44.761658,"marketCap":6057115624},{"date":"2022-11-25","current":6.524573,"twenty":-41.524262,"median":9.120072,"eighty":44.761658,"marketCap":6048278877},{"date":"2022-12-02","current":6.634386,"twenty":-41.524262,"median":9.077138,"eighty":44.761658,"marketCap":6150076230},{"date":"2022-12-09","current":6.425327,"twenty":-41.524262,"median":9.031818,"eighty":44.761658,"marketCap":5956278049},{"date":"2022-12-16","current":6.216944,"twenty":-41.524262,"median":8.981727,"eighty":44.761658,"marketCap":5763107329},{"date":"2022-12-23","current":6.332842,"twenty":-41.524262,"median":8.929251,"eighty":44.761658,"marketCap":5870544977},{"date":"2022-12-30","current":6.29421,"twenty":-41.524262,"median":8.870812,"eighty":44.761658,"marketCap":5834732428},{"date":"2023-01-06","current":6.238017,"twenty":-41.524262,"median":8.723665,"eighty":44.669031,"marketCap":5782641447},{"date":"2023-01-13","current":6.570492,"twenty":-41.524262,"median":8.558011,"eighty":44.528495,"marketCap":6090846415},{"date":"2023-01-20","current":6.436448,"twenty":-41.524262,"median":8.531792,"eighty":44.433823,"marketCap":5966587722},{"date":"2023-01-27","current":6.301234,"twenty":-41.524262,"median":8.3296,"eighty":44.14834,"marketCap":5841243800},{"date":"2023-02-03","current":6.219087,"twenty":-40.702575,"median":8.3296,"eighty":44.14834,"marketCap":5715340826},{"date":"2023-02-10","current":6.142315,"twenty":-11.558641,"median":8.3296,"eighty":44.14834,"marketCap":5644787763},{"date":"2023-02-17","current":6.10452,"twenty":-11.342294,"median":8.3296,"eighty":44.14834,"marketCap":5610053948},{"date":"2023-02-24","current":6.038378,"twenty":-11.297421,"median":8.3296,"eighty":44.14834,"marketCap":5549269770},{"date":"2023-03-03","current":6.122827,"twenty":-11.1811,"median":8.3296,"eighty":44.14834,"marketCap":5626878140},{"date":"2023-03-10","current":5.75019,"twenty":-11.13773,"median":8.3296,"eighty":44.14834,"marketCap":5284424426},{"date":"2023-03-17","current":5.610229,"twenty":-11.066032,"median":8.3296,"eighty":44.14834,"marketCap":5155800765},{"date":"2023-03-24","current":5.809835,"twenty":-10.976285,"median":8.3296,"eighty":44.14834,"marketCap":5339238729},{"date":"2023-03-31","current":6.065544,"twenty":-10.897567,"median":8.324965,"eighty":44.139273,"marketCap":5574234700},{"date":"2023-04-06","current":5.988772,"twenty":-10.820856,"median":8.324965,"eighty":44.139273,"marketCap":5503681637},{"date":"2023-04-14","current":6.134638,"twenty":-10.775982,"median":8.3296,"eighty":44.14834,"marketCap":5637732457},{"date":"2023-04-21","current":6.151764,"twenty":-10.730374,"median":8.3296,"eighty":44.14834,"marketCap":5653471217},{"date":"2023-04-27","current":5.856489,"twenty":-10.606264,"median":8.340928,"eighty":44.166474,"marketCap":5382113282},{"date":"2023-05-05","current":20.861975,"twenty":-10.43882,"median":8.452838,"eighty":44.175541,"marketCap":4693944269},{"date":"2023-05-12","current":20.287633,"twenty":-10.336151,"median":8.558011,"eighty":44.182524,"marketCap":4564717446},{"date":"2023-05-19","current":21.14158,"twenty":-10.102877,"median":8.693871,"eighty":44.189507,"marketCap":4756855455},{"date":"2023-05-26","current":20.227136,"twenty":-9.78508,"median":8.870812,"eighty":44.196491,"marketCap":4551105489},{"date":"2023-06-02","current":19.892072,"twenty":-9.536436,"median":8.929251,"eighty":44.196491,"marketCap":4475716188},{"date":"2023-06-09","current":20.206194,"twenty":-9.454384,"median":8.98113,"eighty":44.203474,"marketCap":4546393658},{"date":"2023-06-16","current":20.073565,"twenty":-9.376314,"median":9.018699,"eighty":44.210457,"marketCap":4516552059},{"date":"2023-06-23","current":19.475569,"twenty":-9.301666,"median":9.056863,"eighty":44.224123,"marketCap":4382003099},{"date":"2023-06-29","current":19.508145,"twenty":-9.246426,"median":9.092642,"eighty":44.237789,"marketCap":4389332615},{"date":"2023-07-05","current":20.315555,"twenty":-9.193781,"median":9.114705,"eighty":44.251456,"marketCap":4570999888},{"date":"2023-07-14","current":20.455165,"twenty":-9.060547,"median":9.163604,"eighty":44.278788,"marketCap":4602412096},{"date":"2023-07-20","current":21.216038,"twenty":-8.93818,"median":19.183552,"eighty":44.278788,"marketCap":4773608633},{"date":"2023-07-28","current":19.591649,"twenty":4.319692,"median":19.750135,"eighty":44.283744,"marketCap":4682404042},{"date":"2023-08-04","current":19.289348,"twenty":4.38581,"median":19.591649,"eighty":44.129229,"marketCap":4610154209},{"date":"2023-08-11","current":19.13927,"twenty":4.38581,"median":19.482306,"eighty":43.956729,"marketCap":4574285498},{"date":"2023-08-18","current":18.466062,"twenty":4.38581,"median":19.154278,"eighty":43.542383,"marketCap":4413388708},{"date":"2023-08-25","current":18.088722,"twenty":4.38581,"median":18.641868,"eighty":43.319191,"marketCap":4323204519},{"date":"2023-08-31","current":18.781226,"twenty":4.38581,"median":18.466062,"eighty":42.973946,"marketCap":4488713001},{"date":"2023-09-08","current":17.87218,"twenty":4.380867,"median":18.294543,"eighty":42.623722,"marketCap":4271451093},{"date":"2023-09-13","current":17.293307,"twenty":4.378395,"median":18.166977,"eighty":42.388429,"marketCap":4133100350},{"date":"2023-09-22","current":18.005107,"twenty":4.319692,"median":17.86146,"eighty":42.077012,"marketCap":4303220523},{"date":"2023-09-29","current":17.479833,"twenty":4.263461,"median":17.50556,"eighty":41.816324,"marketCap":4177680034},{"date":"2023-10-06","current":17.087485,"twenty":4.263461,"median":17.293307,"eighty":41.73771,"marketCap":4083908975},{"date":"2023-10-13","current":16.418565,"twenty":4.263461,"median":16.945983,"eighty":41.577207,"marketCap":3924037005},{"date":"2023-10-20","current":16.294214,"twenty":4.207231,"median":16.495748,"eighty":41.332109,"marketCap":3894317216},{"date":"2023-10-27","current":16.257767,"twenty":-1.056217,"median":16.28671,"eighty":41.192954,"marketCap":3885606243},{"date":"2023-11-03","current":16.332806,"twenty":-6.207204,"median":16.153784,"eighty":40.948113,"marketCap":3903540598},{"date":"2023-11-10","current":15.616718,"twenty":-6.207204,"median":15.881499,"eighty":40.817223,"marketCap":3732395605},{"date":"2023-11-17","current":16.390693,"twenty":-6.207204,"median":15.574911,"eighty":40.340898,"marketCap":3917375673},{"date":"2023-11-24","current":22.827913,"twenty":-6.207204,"median":15.574911,"eighty":39.96161,"marketCap":4063368468},{"date":"2023-12-01","current":23.015098,"twenty":-8.782697,"median":15.533103,"eighty":39.312288,"marketCap":4096687371},{"date":"2023-12-07","current":23.654406,"twenty":-6.207204,"median":15.574911,"eighty":38.926597,"marketCap":4210484243},{"date":"2023-12-15","current":24.893249,"twenty":-8.782697,"median":15.533103,"eighty":38.72267,"marketCap":4430998377},{"date":"2023-12-22","current":24.325418,"twenty":-8.782697,"median":15.533103,"eighty":38.648421,"marketCap":4329924480},{"date":"2023-12-29","current":24.225549,"twenty":-8.789917,"median":12.47951,"eighty":38.641433,"marketCap":4312147664},{"date":"2024-01-05","current":22.661874,"twenty":-8.797137,"median":9.425916,"eighty":38.597758,"marketCap":4033813516},{"date":"2024-01-12","current":23.423737,"twenty":-8.797137,"median":9.425916,"eighty":38.470225,"marketCap":4169425227},{"date":"2024-01-19","current":22.447867,"twenty":-8.804357,"median":9.30281,"eighty":38.332211,"marketCap":3995720339},{"date":"2024-01-26","current":22.718942,"twenty":-8.797137,"median":9.425916,"eighty":38.217781,"marketCap":4043971696},{"date":"2024-02-02","current":28.85349,"twenty":-8.797137,"median":9.425916,"eighty":38.049194,"marketCap":4731972377},{"date":"2024-02-09","current":27.918791,"twenty":-8.797137,"median":9.425916,"eighty":37.903318,"marketCap":4578681720},{"date":"2024-02-16","current":28.325049,"twenty":-8.797137,"median":9.425916,"eighty":37.631656,"marketCap":4645308051},{"date":"2024-02-23","current":28.413632,"twenty":-8.797137,"median":9.425916,"eighty":37.11978,"marketCap":4659835597},{"date":"2024-03-01","current":28.603015,"twenty":-8.789917,"median":12.47951,"eighty":32.879225,"marketCap":4690894489},{"date":"2024-03-08","current":29.339167,"twenty":-8.789917,"median":12.47951,"eighty":32.536971,"marketCap":4811623405},{"date":"2024-03-15","current":29.363604,"twenty":-8.789917,"median":12.47951,"eighty":32.258469,"marketCap":4815631004},{"date":"2024-03-22","current":29.357495,"twenty":-8.789917,"median":12.47951,"eighty":31.941046,"marketCap":4814629104},{"date":"2024-03-28","current":29.81568,"twenty":-8.789917,"median":12.47951,"eighty":31.40619,"marketCap":4889771583},{"date":"2024-04-05","current":29.122292,"twenty":-8.797137,"median":9.425916,"eighty":31.117622,"marketCap":4776055965},{"date":"2024-04-12","current":29.372767,"twenty":-8.797137,"median":9.425916,"eighty":31.051184,"marketCap":4817133853},{"date":"2024-04-19","current":29.168111,"twenty":-8.797137,"median":9.425916,"eighty":30.606254,"marketCap":4783570213},{"date":"2024-04-26","current":29.079528,"twenty":-8.789917,"median":12.47951,"eighty":30.256618,"marketCap":4769042667},{"date":"2024-05-03","current":24.879315,"twenty":-8.789917,"median":12.47951,"eighty":29.945905,"marketCap":4801707860},{"date":"2024-05-10","current":25.416952,"twenty":-8.789917,"median":12.47951,"eighty":29.757033,"marketCap":4905471669},{"date":"2024-05-17","current":25.614345,"twenty":-8.789917,"median":12.47951,"eighty":29.613467,"marketCap":4943568527},{"date":"2024-05-24","current":25.463703,"twenty":-8.789917,"median":12.47951,"eighty":29.5169,"marketCap":4914494609},{"date":"2024-05-31","current":25.87667,"twenty":-8.789917,"median":12.47951,"eighty":29.365437,"marketCap":4994197245},{"date":"2024-06-07","current":26.035104,"twenty":-8.789917,"median":12.47951,"eighty":29.342276,"marketCap":5024774986},{"date":"2024-06-14","current":25.292282,"twenty":-8.797137,"median":9.425916,"eighty":29.274986,"marketCap":4881410496},{"date":"2024-06-21","current":25.066319,"twenty":-8.804357,"median":9.30281,"eighty":29.230424,"marketCap":4837799620},{"date":"2024-06-28","current":24.487127,"twenty":-8.826676,"median":9.172548,"eighty":29.168722,"marketCap":4726015420},{"date":"2024-07-05","current":24.193634,"twenty":-8.826676,"median":9.172548,"eighty":29.132067,"marketCap":4669371408},{"date":"2024-07-12","current":24.601407,"twenty":-8.826676,"median":9.172548,"eighty":29.097856,"marketCap":4748071495},{"date":"2024-07-15","current":24.596212,"twenty":-8.826676,"median":9.172548,"eighty":29.090525,"marketCap":4747068946},{"date":"2024-08-02","current":24.957234,"twenty":-8.929025,"median":9.114705,"eighty":28.735731,"marketCap":4816746093},{"date":"2024-08-09","current":27.237695,"twenty":-8.929025,"median":9.114705,"eighty":28.677936,"marketCap":4058416549},{"date":"2024-08-16","current":27.91282,"twenty":-8.929025,"median":9.114705,"eighty":28.593851,"marketCap":4159010197},{"date":"2024-08-23","current":28.407693,"twenty":-8.929025,"median":9.114705,"eighty":28.535286,"marketCap":4232746318},{"date":"2024-08-30","current":29.413827,"twenty":-8.929025,"median":9.114705,"eighty":28.535286,"marketCap":4382660153},{"date":"2024-09-06","current":28.273324,"twenty":-8.929025,"median":9.114705,"eighty":28.515633,"marketCap":4212725252},{"date":"2024-09-13","current":27.91282,"twenty":-8.929025,"median":9.114705,"eighty":28.437936,"marketCap":4159010197},{"date":"2024-09-20","current":28.840298,"twenty":-8.929025,"median":9.114705,"eighty":28.414125,"marketCap":4297204384},{"date":"2024-09-27","current":28.584668,"twenty":-8.929025,"median":9.114705,"eighty":28.410315,"marketCap":4259115526},{"date":"2024-10-04","current":27.693241,"twenty":-8.929025,"median":9.114705,"eighty":28.328952,"marketCap":4126292846},{"date":"2024-10-11","current":27.781728,"twenty":-8.929025,"median":9.114705,"eighty":28.174035,"marketCap":4139477450},{"date":"2024-10-18","current":28.768197,"twenty":-8.929025,"median":9.114705,"eighty":28.155826,"marketCap":4286461373},{"date":"2024-10-25","current":27.847274,"twenty":-8.929025,"median":9.114705,"eighty":28.143107,"marketCap":4149243823},{"date":"2024-10-31","current":28.55845,"twenty":-8.929025,"median":9.114705,"eighty":28.102675,"marketCap":4255208977},{"date":"2024-11-08","current":23.317939,"twenty":-8.93818,"median":9.109339,"eighty":27.987673,"marketCap":3940731747},{"date":"2024-11-15","current":22.552233,"twenty":-8.93818,"median":9.109339,"eighty":27.96198,"marketCap":3811327297},{"date":"2024-11-22","current":21.642415,"twenty":-8.93818,"median":9.127228,"eighty":27.96083,"marketCap":3657568070},{"date":"2024-11-29","current":21.759491,"twenty":-8.93818,"median":9.172548,"eighty":27.96083,"marketCap":3677353987},{"date":"2024-12-06","current":21.310698,"twenty":-8.93818,"median":16.14628,"eighty":27.96083,"marketCap":3601507972},{"date":"2024-12-13","current":20.66399,"twenty":-8.93818,"median":16.326374,"eighty":27.96083,"marketCap":3492214336},{"date":"2024-12-20","current":20.056308,"twenty":-8.93818,"median":16.418565,"eighty":27.96083,"marketCap":3389516005},{"date":"2024-12-27","current":20.109271,"twenty":-8.93818,"median":16.564355,"eighty":27.96083,"marketCap":3398466777},{"date":"2025-01-03","current":19.440263,"twenty":-8.93818,"median":16.920255,"eighty":27.96083,"marketCap":3285404395},{"date":"2025-01-10","current":19.6399,"twenty":-8.938327,"median":17.089629,"eighty":27.96106,"marketCap":3319143109},{"date":"2025-01-17","current":19.75157,"twenty":-8.938327,"median":17.49484,"eighty":27.96106,"marketCap":3338015281},{"date":"2025-01-24","current":20.086579,"twenty":-8.938327,"median":17.759622,"eighty":27.96106,"marketCap":3394631794},{"date":"2025-01-31","current":-136.701619,"twenty":-9.032373,"median":17.86146,"eighty":27.96106,"marketCap":3007435623},{"date":"2025-02-07","current":-139.725612,"twenty":-9.144874,"median":17.86146,"eighty":27.96106,"marketCap":3073963459},{"date":"2025-02-14","current":-139.361017,"twenty":-9.245709,"median":17.86146,"eighty":27.96106,"marketCap":3065942372},{"date":"2025-02-21","current":-140.326121,"twenty":-9.301666,"median":17.86146,"eighty":27.96106,"marketCap":3087174660},{"date":"2025-02-28","current":-131.897546,"twenty":-9.377985,"median":17.86146,"eighty":27.96106,"marketCap":2901746013},{"date":"2025-03-07","current":-127.90845,"twenty":-9.455107,"median":17.87218,"eighty":27.96129,"marketCap":2813985889},{"date":"2025-03-14","current":-119.994597,"twenty":-9.579026,"median":17.87218,"eighty":27.96129,"marketCap":2639881128},{"date":"2025-03-21","current":-119.823023,"twenty":-9.954842,"median":17.87218,"eighty":27.96129,"marketCap":2636106499},{"date":"2025-03-28","current":-128.144364,"twenty":-10.210799,"median":17.87218,"eighty":27.96129,"marketCap":2819176004},{"date":"2025-04-04","current":-113.839378,"twenty":-10.377935,"median":17.87218,"eighty":27.96129,"marketCap":2504466314},{"date":"2025-04-11","current":-104.209785,"twenty":-10.499986,"median":17.86146,"eighty":27.96106,"marketCap":2292615264},{"date":"2025-04-17","current":-106.268673,"twenty":-10.617545,"median":17.86146,"eighty":27.96106,"marketCap":2337910812}],"updateTime":1745124839149}}}